semaglutide cardiovascular outcomes news today 2025 🔴Cardiovascular with by severity of chronic kidney disease in type 2 diabetes: the FLOW trial⤵️ 🔹Semaglutide significantly reduced the risk of CV death/MI/stroke regardless of baseline CKD severity in participants ADA 2025: Oral Semaglutide Demonstrates

prescribers should verify current supply.) Tirzepatide (Mounjaro) a dual GIP/GLP-1 receptor agonist administered as a once-weekly subcutaneous injection, licensed for type 2 diabetes

Clinical studies demonstrate its effectiveness at raising blood glutathione levels when taken consistently

At low doses, naltrexone briefly blocks opioid receptors, prompting the body to produce more natural endorphins

14% of all adults) and 27% hold a masters degree or higher (vs

1 Despite these constraints, the commercial consequence has been significant: Medicare logged $27.5 billion in gross GLP-1 spending across 21.8 million claims in 2024, entirely under FDA-approved indications other than obesity